Popular Articles

Sanofi Pasteur Responds To Nation's Need For Hib Vaccine With Increased Supply
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that the company has been able to increase the supply of its Hib-containing vaccines to enable the return to a full series of vaccinations for U.S. children. Based on the increased supply, on July 1, the U.S. Centers for Disease Control and Prevention (CDC) will reinstate its recommendation that children receive a booster dose of Haemophilus influenzae type b (Hib) vaccine after 12 months of age. The CDC also provided guidance on a phased approach to immunize children whose booster dose was previously deferred at their next regularly scheduled medical visit. The CDC had recommended a temporary deferral of the booster dose of Hib vaccine in 2007 due to supply constraints caused by another manufacturer"s withdrawal of Hib vaccine from the market. Since that time, Sanofi Pasteur has been, and continues to be, the sole supplier of Hib vaccine to the U.S. market.
pharmacy online
Study Pinpoints Drugs That Prevent Epilepsy, Seizures After Severe Brain Injury
Drugs that block a growth factor receptor on brain cells may prevent epilepsy after brain damage, according to a new study appearing in the July 15 issue of the Journal of Neuroscience.
News of the day
New Ovarian Transplantation Technique Gives Greatly Improved Results In This Delicate Operation
Ultra-fast freezing of ovarian tissue from women who have lost their fertility as a result of cancer treatment can lead to it being used in transplants with the same success rate as fresh tissue, a researcher told the 25th annual conference of the European Society of Human Reproduction and Embryology 29 June. Dr. Sherman Silber, Director of the St. Louis Infertility Centre, St. Louis, Missouri, USA, said that freezing tissue by the vitrification method, which avoids ice formation, meant that oocyte (egg) viability was almost identical with that seen in fresh oocytes.
Health Insurance

FDA Clears Osmetech's Cystic Fibrosis Genotyping Test

Osmetech plc (LSE:OMH), the fast growing international molecular diagnostics company announces that it has received US Food & Drug Administration ("FDA") 510(k) clearance for its eSensor® Cystic Fibrosis Genotyping Test for use on the eSensor® XT-8 System. This multiplex test is used for cystic fibrosis carrier screening for adults of reproductive age, as an aid in newborn screening for cystic fibrosis, and as a confirmatory diagnostic test for cystic fibrosis in newborns and children. This is the second FDA 510(k) cleared multiplex test the company has for use on the eSensor XT-8 System and follows clearance of a Warfarin Sensitivity Test. The Warfarin Sensitivity Test is used as an aid in the identification of patients at risk for increased sensitivity to the widely used blood-thinning drug warfarin. Osmetech expects further commercial progress in 2009 by expanding the eSensor XT-8 test menu to include an extended Warfarin Sensitivity Test panel that includes CYP 4F2, a CYP 2C9 Genotyping panel, a venous thrombosis panel of Factor V, Factor II and MTHFR and a Respiratory Virus Pathogen panel. James White, Chief Executive, Osmetech plc, commented: "This FDA clearance marks the start of the broadening of the menu of FDA cleared tests available to our growing base of eSensor XT-8 System customers. Our proprietary, multiplexed DNA eSensor technology allows for the rapid development of new tests which we plan to commercialise globally consistent with market demands." "We have been delighted with the excellent operational performance of our eSensor XT-8 System in the market and we will now transition our first generation eSensor 4800 cystic fibrosis carrier detection customers over to the eSensor XT-8 System, enabling them to benefit from its many advantages including greater ease of use and widening test menu." Osmetech plc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):